GSK, Singapore's A*STAR Unite For EBF Drugs For Emerging Markets
This article was originally published in PharmAsia News
Executive Summary
GlaxoSmithKline Plc is joining with Singapore's Agency for Science, Technology and Research for a five-year study of reformulated drugs to meet a growing demand in the BRIC nations and other emerging markets.